14 фев 2018 г. - FDA held a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss the new drug application for Hydexor (proposed tradename), a fixed-dose combination oral tablet, submitted by Charleston Laboratories, Inc., that contains hydrocodone, acetaminophen, and promethazine, for the short- term management of acute pain severe enough to require an opioid analgesic while preventing and reducing opioid-induced nausea
Добавлено на ленту времени:
Дата:
14 фев 2018 г.
Сейчас
~ 7 гг и 8 мес назад